Compare Viatris Inc (VTRS) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Clear Secure Inc — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Clear Secure Inc trades at $57.03 (market cap $5.76B). The key difference: Viatris Inc is far larger — about 3.4× Clear Secure Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VTRS | YOU | |
|---|---|---|
Market Cap | $19.79B | $5.76B |
Sector | Health | Technology |
52-Week High | $17.39 | $62.36 |
52-Week Low | $8.74 | $28.84 |
Enterprise Value | $32.00B | $5.07B |
Dividend Yield | 2.83% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Clear Secure (YOU) trades at $57.18, up 2.05% with a bullish technical outlook. The stock shows strong profitability with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated with a P/E of 45.74. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected. The company continues expanding airport partnerships and launched AWS integration for contact center verification in June 2026.
Growth prospects remain positive with revenue projected to reach $942 million in 2026, but high valuation multiples and mixed analyst ratings (44% Buy, 44% Hold) suggest cautious optimism. Key risks include execution of expansion plans and competitive pressures in identity verification markets. The consensus price target of $56.67 offers limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
